This document summarizes information about hepatitis C and B infections in patients co-infected with HIV. It finds that HCV coinfection is a major cause of mortality and morbidity in the HIV population. Less than 20% of coinfected patients have received HCV treatment in Europe. HBV coinfection accelerates liver fibrosis and damage in HIV patients compared to HBV mono-infected patients. Antiviral therapies like lamivudine, adefovir, entecavir and pegylated interferon have demonstrated efficacy against HBV in coinfected patients.
Presentazione a cura del Dottor Claudio Puoti - "HOT TOPICS IN GASTROENTEROLOGIA - I TUMORI DELL'APPARATO DIGERENTE: cosa è cambiato e cosa bisogna sapere" - Roma 10/11/2018
Presentazione a cura del Dottor Claudio Puoti - "HOT TOPICS IN GASTROENTEROLOGIA - I TUMORI DELL'APPARATO DIGERENTE: cosa è cambiato e cosa bisogna sapere" - Roma 10/11/2018
Susanna Naggie, M.D., M.H.S., of Duke Clinical Research Center, presents "HIV/HCV Co-Infection: The Journey of a Special Population" at AIDS Clinical Rounds
HIV/AIDS Update From Boston 2014.CCO Official Conference Coverage.March 3-6,2014Hivlife Info
Topics covered include:
* First -line raltegravir, atazanavir/ritonavir, or darunavir/ritonavir
* Switching to elvitegravir-based therapy
* 92-week data on first-line dolutegravir
* Risk of HIV transmission with undetectable viral load
* Latest insights from cure research
New hepatitis C virus treatments
Susanna Naggie, M.D., M.H.S., of Duke Clinical Research Center, presents "HIV/HCV Co-Infection: The Journey of a Special Population" at AIDS Clinical Rounds
HIV/AIDS Update From Boston 2014.CCO Official Conference Coverage.March 3-6,2014Hivlife Info
Topics covered include:
* First -line raltegravir, atazanavir/ritonavir, or darunavir/ritonavir
* Switching to elvitegravir-based therapy
* 92-week data on first-line dolutegravir
* Risk of HIV transmission with undetectable viral load
* Latest insights from cure research
New hepatitis C virus treatments
Hepatitis And Hiv Co Infection Tonia Poteat 060508elfaye
A presentation by Tonia Poteat from the CDC Global AIDS Project on the topic of Hepatitis B & C and HIV Co-infection. This webcast was presented live to ECHO (Evaluation Center for HIV and Oral Health) grantees on June 5, 2008.
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...hivlifeinfo
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Contemporary Management of HIV. Managing HIV in Viral Hepatitis Coinfection.2016
In this downloadable slideset, David L. Wyles, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for ART management in patients with HIV and viral hepatitis coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 1.85 MB
A slideshow for my collegues in hospitals on 2014 Oct 15th.
This presentation is about a case who developed resistance to lamivudine, an anti-HBV agent, during treatment. We discussed about how resistance develop, how to interpret resistance result, and how to optimize the therapy in lamivudine-resistant settings. Time to stop anti-viral agents is also discussed.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
2. Causes de décès d’origine infectieuse dans le monde (2000) HIV – HBV – HCV : TOP 10 Maladies Infections respiratoires VIH Diarrhées Tuberculose Malaria Rougeole Hépatite B Pertussis Tétanos néonatal Hépatite C Décès par an ~3,5 million ~3,0 million ~2,2 million ~2,0 million ~1-3 million ~888,000 ~750,000 ~355,000 ~300,000 ~ 250,000 Source : CDC, WHO, UNICEF, UNAIDS
3. Viral hepatitis in HIV-infected patients Hepatotoxicity of anti-retroviral therapies Progression to Cirrhosis Mortality Prevalence Active consideration for treatment of hepatitis ? Controversies ? Accelerated Higher compare to HBV mono-infected Major cause of death 7%-10% 20%-35% HBV HCV
6. No influence of HCV/HBV on response to HAART : EuroSIDA cohort Konopnicki D et al. AIDS. 2005;19:593-601. HIV RNA <400 copies/ml 50% rise in CD4 10 30 50 70 0 3 6 9 12 10 30 50 70 HCV
7. Influence du VIH sur le VHC Mortalité liée à l’atteinte hépatique Mortalité chez les patients VIH en France Étude du groupe GERMIVIC Caboub et al, CID 2001; Rosenthal et al, AIDS 2003. % Mortalité Globale Mortalité liée au Sida Mortalité liée au foie CHC 8 91,6 1,5 6,9 2 84,5 6,6 8,8 1 48,7 14,3 36,7 1 47 12,6 40,4
8. Impact of HAART on liver related mortality Qurishi N et al, Lancet 2003 Days of observation 5000 4000 3000 2000 1000 0 Survival 1.1 0.9 0.7 0.5 0.3 p < 0,0001 HAART ARV Untreated 6000 6000 5000 4000 3000 2000 1000 0 1.1 0.9 0.7 0.5 0.3 p < 0,018 HAART ARV Untreated Survival Global Mortality Liver Mortality Days of observation
9. Progression to cirrhosis influence of alcohol and immune status Benhamou et al. Hepatology 1999;30:1054-1058 Estimated duration of HCV infection Fibrosis (METAVIR) CD4<200/µL OH>50 g/j CD4 <200/µL OH <50 g/j CD4 >200/µL OH<50 g/j HIV- OH<50 g/j
12. PEG IFN/RBV Virological response GT 1 GT 4 GT 1/4 GT 2/3 RBV 800 mg 24 weeks Torriani F et al. NEJM 2004. Carrat F et al. JAMA 2004. Laguno C ett al. AIDS 2004. Chung R. NEJM. 2004 GT2/3, Rx 48 w
14. Impact of HCV RNA on SVR Torriani F et al. NEJM. 2004. GT 1 GT 2/3 Cooper D. et al, XV AIDS Conference HCV RNA Liver evaluation for GT1, high HCV RNA 21 (43 %) 49 > 5000 cp/mL 23 (35 %) 66 50-5000 cp/mL 72 (42 %) 173 < 50 cp/mL HIV RNA 90 (47 %) 216 ≥ 350 / L 26 (36 %) 72 < 350 / L 8 (47 %) 17 < 200/ L CD4 SVR N
15. APRICOT SVR according to Rx exposure *Patients violated the rule if ≥1 of the three targets were not achieved Opravil M. et al. 45th ICAAC 2005; Abstract 2038 GT1 GT2/3 39% SVR rate (%) ≥ 80/80/80 exposure 0 10 20 30 40 50 11% <80/80/80 exposure* 62 29% All patients n = 176 114 69% SVR rate (%) ≥ 70/70/70 exposure 0 20 40 60 80 100 26% <70/70/70 exposure* 27 59% All patients n = 111 84
25. 0 0.25 0.50 0.75 1 0 75 150 225 300 Follow up (months) Proportion of patients free Of liver decompensation HIV – (n=504) HIV + (n=164) P=0.004 Liver decompensation in HBsAg+ Benhamou et al. CROI 2005
26.
27.
28.
29. HIV/HBV FTC Log 10 HBV DNA 24 22 20 20 17 33 33 33 33 33 10 10 10 7 7 FTC HBV+HIV FTC HBV d4T HBV+HIV FTC is not licensed for the treatment of HBV. Raffi F. IAS Conference, July 13-16, 2003, Abstract # 215. FTC HBV+HIV d4T HBV+HIV FTC in Chronic HBV (FTCB-102)
30. HIV/HBV LAM-R: ETV ETV PBO 5.56 HBV DNA (log 10 copies/ml) 9.19 4.79 5.63 Weeks RDZ double binded phase All the patients: ETV 1.0 mg Pessoa et al. ICAAC 2005
33. Peters M et al. CROI 2005. HIV/HBV ADV vs TDF *Roche Cobas Amplicor, LLQ 200 copies/mL ADV TDF HBV DNA (log 10 c/mL)* ADV 25 24 23 20 18 17 TDF 27 26 23 18 17 18
34. HIV/HBV: anti-HBV therapy * Added to LMV in the majority of the cases. ** < 6log copies/ml Wong DK et al. Gastroenterology 1995. Di Martino V et al. Gastroenterology 2002. Dore GJ et al. J Infect Dis 1999 .Benhamou Y et al. Hepatology 1996. Pessoa W et al. CROI 2005. Raffi F et al. 2003 IAS. Peter M et al. CROI 2005.. Ristig MB et al. J Infect Dis. 2002. Benhamou Y et al. N Engl J Med. 2003 . Benhamou Y et al. Lancet 2001 and AASLD, 2003 No yes yes YES? Yes Poor Anti HIV activity ? 49% ? 3.6 wt, preC, LAM-R?? 24 51 ETV* wt, preC, LAM-R wt, preC LAM-R wt, preC wt, preC wt, preC Anti-HBV activity ADV* TDF* FTC LAM IFN 33-50% 35-66% 7% 4 - 5.4 48-144 35 ? 12-20% 9% 26%** 12-24 87 ? ? ? Histological improvement ? ? 30-50% ALT response 4% ? 11% HBe seroconv. 4.4 3 2.7 HBV DNA decline (log cp/ml) 24-48 48 48 Duration (weeks) 200 33 215 No. of patients
35. HBV resistance Lai C et al. N Engl J Med 1998 . Leung N et al. J Hepatol 1999 . Chang T et al. Antiv Ther 2000 . Benhamou Y et al. Hepatology 1999 . Benhamou Y et al. Lancet 2001 and AADSL 2003. Data on file. NV-02B-003. Idenix. HIV/HBV HBV Patients (%)
36. Treatment Algorithm Patients with Compensated Disease and No indication for HIV therapy
37. Treatment Algorithm Patients with Compensated Disease and indication for HIV therapy